Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

Inclusion Criteria:

• Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive);
• Body Mass Index (BMI) of ≥18 and <40 kg/m2;
• History or symptoms consistent with motion sickness

Exclusion Criteria:

• Chronic nausea due to condition other than motion sickness;
• A positive test for drugs of abuse at the screening or evaluation visits;
• Clinically significant deviation from normal clinical laboratory results

All Adverse Events (AEs) were collected from the time of the subject's informed consent signature until the end of the subject's study participation. AEs reported or learned up to 7 days after the subject's last study visit or a new SAE(s) up to 30 days after last study visit were recorded. AEs were monitored for approximately one month after randomization.